This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

CSCO - XIAMEN, CHINA, 19-23 September 2018

Oral Presentation: Afatinib in chemotherapy pre-treated EGFR mutation-positive NSCLC

Sumitra Thongprasert, Sarayut L. Geater, Dana Clement, Amr Abdelaziz, Jasmin Reyes-Igama, Dragana Jovanovic, Aurelia Alexandru, Michael Schenker, Virote Sriuranpong, Piotr Serwatowski, Sheethal Suresh, Agnieszka Cseh, Rabab Gaafar

1200.217_Thongprasert CSCO oral pesentation

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Yang JC, et al. Lancet Oncol. 2012 May;13(5):539-48.

FOR HEALTHCARE PROFESSIONALS ONLY In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications. In Switzerland, Afatinib is approved as monotherapy for patients with non-small cell lung cancer (NSCLC, stage IIIb/IV) with activating mutations of EGFR (exon 19 deletions or exon 21 L858R substitutions), not previously treated with EGFR TKIs. It is also indicated for the treatment of patients with locally advanced or metastatic squamous cell cancer of the lung whose carcinoma progressed during or after platinum-based chemotherapy and for whom immunotherapy is not suitable.